National Center for Advancing and Translational Sciences Genetic and Rare Diseases Information Center, a program of the National Center for Advancing and Translational Sciences

Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency



Other Names:
Classic 21-OHD CAH
This disease is grouped under:

The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.
orphanet

Orpha Number: 90794

Definition
A disorder that is the most common form of congenital adrenal hyperplasia (CAH), characterized by simple virilizing or salt wasting forms that can manifest with genital ambiguity in females and with adrenal insufficiency (in both sexes), and that presents with dehydration, hypoglycemia in the neonatal period (that can be lethal if untreated), and hyperandrogenia.

Epidemiology
The prevalence is about 1/14,000.

Clinical description
Classic 21-OHD CAH can be divided into 2 clinical groups: simple-virilizing or salt wasting (see these terms). Clinical signs of classic 21-OHD CAH are observed prenatally or at birth. Girls present with ambiguous genitalia (clitoromegaly, partially fused labia majora with rugae, common urogenital sinus) and the extent of virilization can vary from a nearly male appearance to minimal clitoromegaly. A normal uterus and various degrees of abnormal vaginal development are seen. The external genitalia in boys are normal. Salt wasting forms of CAH lead to symptoms of dehydration and hypotension in the first few weeks of life due to aldosterone deficiency. They can develop failure to thrive, hyponatremia, hyperkalemia, acidosis and hypoglycemia which can be life threatening if not treated immediately. Hyperandrogenia manifests with accelerated growth velocity and accelerated skeletal maturation (leading to short stature in adulthood), advanced bone age, premature pubarche and precocious puberty during childhood, acne and hirsutism, menstrual problems, subfertility, and metabolic disturbances and obesity during adulthood.

Etiology
The disease is caused by a mutation in the CYP21A2 gene located on chromosome 6p21.3 which controls cortisol and aldosterone production.

Diagnostic methods
Diagnosis of girls with classic 21-OHD CAH is usually at birth when ambiguous genitalia are present. Fetuses can be diagnosed for CAH prenatally by measuring 17-hydroxy-progesterone (17-OHP) levels found in amniotic fluid. National systematic screening programs in most European countries diagnose cases of CAH at birth.

Differential diagnosis
Differential diagnoses include other forms of CAH, polycystic ovary syndrome (PCOS, see these terms) or any diseases with androgen excess.

Antenatal diagnosis
Prenatal testing is available by either chorionic villus sampling (CVS) during the 10th -12th week of gestation or by amniocentesis during the 15th -18th week by measuring the enzyme activity of 17-OHP.

Genetic counseling
As classic 21-OHD CAH follows an autosomal recessive pattern of inheritance, genetic counseling is possible.

Management and treatment
Prenatal treatment with dexamethasone can be administered to female fetuses at risk of developing classic CAH. When administered before the 9th week of gestation, it prevents the excessive androgen production responsible for genital ambiguity in females. If diagnosed after birth, vaginoplasty surgery is usually performed on girls in the first year of life. Lifelong hormone replacement therapy is needed to treat adrenal insufficiency and to decrease elevated androgen hormone levels in order to allow for normal growth and puberty. Hydrocortisone is usually given to children as glucocorticoid (GC) replacement therapy (10-15mg/m2/day divided into 2 or 3 doses) and 9alpha-fludrocortisone for mineralocorticoid (MC) replacement. Dosage is monitored and modified during times of stress. There is a risk of developing acute adrenal insufficiency (see this term) and other complications due to chronic hyperandrogenemia. Excessive treatment with GC causes cushingoid features, and excess MC causes hypertension. Regular follow-up by a multidisciplinary team, including pediatric endocrinologists, surgeons, gynecologists, psychologists, is important.

Prognosis
With proper treatment patients have a normal life expectancy.

Visit the Orphanet disease page for more resources.
Last updated: 10/1/2012

The symptoms of 21-hydroxylase deficiency may be different from person to person. Some people may be more severely affected than others, even people who have the same form. Not everyone with 21-hydroxylase deficiency will have the same symptoms, and some may have few or no symptoms.

There are three forms of 21-hydroxylase deficiency: the classic salt wasting form, the simple virilizing form, and the non-classic form. Most patients with 21-hydroxylase deficiency will have the classic salt-wasting form or the simple virilizing form.[1]

Infants with the severe classic salt wasting form develop symptoms within the first few weeks of life. These include:[2][3][1]
  • Salt wasting crisis
    • low sodium levels (hyponatremia)
    • high potassium levels (hyperkalemia)
    • high levels of renin in the blood (hyperreninemia)
    • low blood volume (hypovolemic shock)
  • Ambiguous genitalia in female newborns babies (genitalia that is not typical female nor male appearing), with normal internal feminine reproductive organs (ovaries, uterus, and fallopian tubes); male babies usually have normal genitalia but may have small testes and an enlarged penis.
Salt wasting crises can be life-threatening and require immediate treatment.  

Infants with the classic simple virilizing form may have:
  • Ambiguous external genitalia in female babies with normal internal reproductive organs; males are born with normal genitalia and may have small testes and an enlarged penis
Later in life both males and females with both classic forms of 21-hydroxylase deficiency may have:
  • Puberty starting in childhood (precocious puberty)
  • Excessive hair growth
  • Acne
  • Shorter than average adult height
  • Reduced fertility
  • Irregular periods (females)
  • Testicular enlargement and testicular tumors (males)
Females with the non-classic type of 21-hydroxylase deficiency have normal female genitalia, but when they get older, symptoms may include excessive hair growth (hirsutism), male pattern baldness, irregular periods and reduced fertility. Males with the non-classic type may have early beard growth, an enlarged penis, and small testes. The non-classical form is not considered a rare disease and some people with this form of 21-hydroxylase deficiency may not experience any signs or symptoms.
Last updated: 4/11/2019

This table lists symptoms that people with this disease may have. For most diseases, symptoms will vary from person to person. People with the same disease may not have all the symptoms listed. This information comes from a database called the Human Phenotype Ontology (HPO) . The HPO collects information on symptoms that have been described in medical resources. The HPO is updated regularly. Use the HPO ID to access more in-depth information about a symptom.

Showing of 57 |
Medical Terms Other Names
Learn More:
HPO ID
80%-99% of people have these symptoms
Abnormality of hair growth rate
Abnormality of pace of hair growth
Abnormality of speed of hair growth
[ more ]
0011363
Accelerated bone age after puberty 0002805
Acidosis 0001941
Adrenogenital syndrome 0000840
Congenital adrenal hyperplasia 0008258
Decreased circulating aldosterone level
Low blood aldosterone level
0004319
Decreased circulating cortisol level
Low blood cortisol level
0008163
Dehydration 0001944
Elevated circulating follicle stimulating hormone level 0008232
Elevated circulating luteinizing hormone level 0011969
Enlarged polycystic ovaries
Enlarged ovaries with cysts
0008675
Feeding difficulties
Feeding problems
Poor feeding
[ more ]
0011968
Hirsutism
Excessive hairiness
0001007
Hyperkalemia
Elevated serum potassium levels
0002153
Hypernatriuria 0012605
Hyponatremia
Low blood sodium levels
0002902
Hypotension
Low blood pressure
0002615
Hypovolemia
Depleted blood volume
0011106
Increased circulating ACTH level
High blood corticotropin levels
0003154
Increased circulating androgen level 0030348
Increased circulating renin level
Elevated blood renin level
0000848
Irregular menstruation
Menstrual irregularity
0000858
Neonatal hypoglycemia
Low blood sugar in newborn
0001998
Osteoporosis 0000939
Premature adrenarche 0012412
Short stature
Decreased body height
Small stature
[ more ]
0004322
Vomiting
Throwing up
0002013
30%-79% of people have these symptoms
Abnormal oral glucose tolerance 0004924
Abnormal scrotal rugation 0012856
Abnormal spermatogenesis 0008669
Abnormality of circulating leptin level 0004361
Acne 0001061
Adrenocorticotropic hormone excess 0011749
Ambiguous genitalia, female
Atypical appearance of female genitals
0000061
Aortic root aneurysm
Bulge in wall of root of large artery that carries blood away from heart
0002616
Clitoral hypertrophy
Enlarged clitoris
0008665
Decreased fertility in females
Reduced fertility in females
0000868
Decreased fertility in males 0012041
Female sexual dysfunction 0030014
Fused labia minora
Fused inner lips
0000063
Generalized hyperpigmentation 0007440
Hyperpigmented genitalia
Increased genital pigmentation
0030258
Hypertension 0000822
Long penis
Enlarged penis
0000040
Obesity
Having too much body fat
0001513
Urogenital sinus anomaly 0100779
5%-29% of people have these symptoms
Adrenal medullary hypoplasia 0008239
Adrenocortical adenoma 0008256
Aggressive behavior
Aggression
Aggressive behaviour
Aggressiveness
[ more ]
0000718
Ectopic adrenal gland
Abnormal adrenal gland position
0011742
Failure to thrive
Faltering weight
Weight faltering
[ more ]
0001508
Female pseudohermaphroditism 0010458
Gynecomastia
Enlarged male breast
0000771
Insulin resistance
Body fails to respond to insulin
0000855
Intellectual disability
Mental deficiency
Mental retardation
Mental retardation, nonspecific
Mental-retardation
[ more ]
0001249
Maternal virilization in pregnancy 0008072
Renal salt wasting
Loss of salt in urine
0000127
Showing of 57 |
Last updated: 7/1/2020

21-hydroxylase deficiency is inherited in an autosomal recessive pattern.[3]  All individuals inherit two copies of each gene. To have 21-hydroxylase deficiency, a person must have a mutation in both copies of the responsible gene in each cell. There is nothing either parent can do, before or during a pregnancy, to cause a child to have this.
 
People with autosomal recessive conditions inherit one mutation from each of their parents. The parents, who each have one mutation, are known as carriers. Carriers of an autosomal recessive disorder typically do not have any signs or symptoms (they are unaffected). When two carriers of an autosomal recessive condition have children, each child has a:

25% (1 in 4) chance to have the disorder

50% (1 in 2) chance to be an unaffected carrier like each parent

25% (1 in 4) chance to be unaffected and not be a carrier

Last updated: 4/9/2019

Babies born in the USA are screened at birth through newborn screening for the classic salt wasting and simple virilizing forms of 21-hydroxylase deficiency.  For babies that test positive on the newborn screen for this disorder, additional biochemical and genetic testing is done to confirm the diagnosis.[4] The less severe, non-classical form of 21-hydroxylase def is diagnosed based on the clinical symptoms, biochemical testing to look for excess hormone production. Genetic testing may also be helpful to determine the type and severity of 21-hydroxylase deficiency.[5]
Last updated: 4/11/2019

Newborn Screening

  • Baby's First Test is the nation's newborn screening education center for families and providers. This site provides information and resources about screening at the local, state, and national levels and serves as the Clearinghouse for newborn screening information.

Treatment for 21-hydroxylase deficiency depends on the severity of symptoms and the form of the condition. The goals of treatment are to manage to symptoms. Infants identified at birth with 21-hydroxylase deficiency are treated with hormones and steroids to prevent a salt-wasting crisis. In childhood and adulthood, other medications may be used to improve growth and fertility. Males should be monitored for the growth of testicular adrenal rest tumors, a benign tumor that can cause infertility. In some cases, females with ambiguous genitalia may be offered surgical correction. Some people with this condition have psychological issues and may benefit from therapy.[4][6]

At least one organization has published clinical practice guidelines for 21-hydroxylase deficiency.
Last updated: 4/11/2019

The long-term outlook for people with 21-hydroxylase deficiency is dependent on the severity of the symptoms, the response to medications and the presence of any other medical conditions. In general, with early diagnosis and continuous lifetime treatment, the long-term outlook for people with this disorder is good. Long term complications of this condition may include fertility and mental health issues.[6] 
Last updated: 4/11/2019

Approximately 1 in 10 to 15,000 people in the United States has congenital adrenal hyperplasia due to classic 21-hydroxylase deficiency.[2][1] The prevalence is higher is other parts of the world.  
Last updated: 4/11/2019

Support and advocacy groups can help you connect with other patients and families, and they can provide valuable services. Many develop patient-centered information and are the driving force behind research for better treatments and possible cures. They can direct you to research, resources, and services. Many organizations also have experts who serve as medical advisors or provide lists of doctors/clinics. Visit the group’s website or contact them to learn about the services they offer. Inclusion on this list is not an endorsement by GARD.

Organizations Supporting this Disease


These resources provide more information about this condition or associated symptoms. The in-depth resources contain medical and scientific language that may be hard to understand. You may want to review these resources with a medical professional.

In-Depth Information

  • The Monarch Initiative brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch’s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.
  • Orphanet is a European reference portal for information on rare diseases and orphan drugs. Access to this database is free of charge.

Questions sent to GARD may be posted here if the information could be helpful to others. We remove all identifying information when posting a question to protect your privacy. If you do not want your question posted, please let us know.


  1. Parsa AA, New MI. Steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia. Jl Steroid Biochem Mol Biol. Jan 2017; 165(pt A):2-11. https://www.ncbi.nlm.nih.gov/pubmed/27380651.
  2. Congenital Adrenal Hyperplasia. National Organization of Rare Disorders (NORD). Updated 2018; . https://rarediseases.org/rare-diseases/congenital-adrenal-hyperplasia/.
  3. 21-hydroxylase deficiency. Genetics Home Reference (GHR). March, 2015; https://ghr.nlm.nih.gov/condition/21-hydroxylase-deficiency.
  4. Nimkarn A, Gangishetti PK, Yau M, New MI. 21-Hydroxylase-Deficient Congenital Adrenal Hyperplasia. GeneReviews. Updated Feb 4, 2016; http://www.ncbi.nlm.nih.gov/books/NBK1171/.
  5. Concolino P, Costella A. Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency: A comprehensive focus on 233 pathogenic variants of CYP21A2 gene. Mol Diagn Ther. Jun 2018; 22(3):261-280. https://www.ncbi.nlm.nih.gov/pubmed/29450859.
  6. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP et al.. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: An Endocrine Society clinical practice guideline. Jl Clin Endo Metab. Nov 2018; 103(11):4043-4088. https://www.ncbi.nlm.nih.gov/pubmed/30272171.